

Contents

1.	Introduction	1
2.	General policy	6
2.1	International collaboration	6
2.1.1	Collaboration with international organizations and agencies	6
2.1.2	Pharmacopoeial Discussion Group	7
2.1.3	International Conference on Harmonisation	7
2.1.4	International Conference of Drug Regulatory Authorities	8
2.2	Cross-cutting pharmaceuticals – quality assurance issues	8
2.2.1	Biological standardization	8
2.2.2	Essential medicines	9
2.2.3	Herbal and complementary medicines	9
2.2.4	Working group meeting on substandard/spurious/false-labelled/falsified/counterfeit medical products	10
3.	Quality control – specifications and tests	10
3.1	<i>The International Pharmacopoeia</i>	10
3.1.1	Fourth edition update	10
3.1.2	Outreach with stakeholders	11
3.1.3	Annotated work plan	11
3.1.4	Monograph development	12
3.2	Specifications for medicines, including children's medicines	12
3.2.1	Medicines for HIV and related conditions	12
3.2.2	Antimalarial medicines	13
3.2.3	Antituberculosis medicines	14
3.2.4	Anti-infectives	14
3.2.5	Other medicines	15
3.2.6	Other paediatrics	16
3.3	General monographs for dosage forms and associated method texts	16
3.3.1	Pharmacopoeial Discussion Group-harmonized general texts	16
3.3.2	Uniformity of content single-dose preparations	21
3.3.3	General monograph on tablets	23
3.4	Preface, general notices and supplementary information sections of <i>The International Pharmacopoeia</i>	24
4.	Quality control – International Reference Materials (International Chemical Reference Substances and Infrared Reference Spectra)	25
4.1	Update on International Chemical Reference Substances	25
4.1.1	Report on activities of the host organization related to International Chemical Reference Substances	25
4.1.2	Frequently asked questions about collaborative trials	26
4.1.3	Annual report on International Chemical Reference Substances 2010	26
4.1.4	Lumefantrine for system suitability testing	27
4.1.5	Bacterial endotoxin	27

5.	Quality control – national laboratories	27
5.1	External Quality Assurance Assessment Scheme	27
6.	Quality assurance – good manufacturing practices	29
6.1	WHO good manufacturing practices: water for pharmaceutical use	29
7.	Quality assurance – new approaches	29
7.1	WHO guidelines on quality risk management	29
8.	Quality assurance – distribution and trade of pharmaceuticals	29
8.1	WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce	29
8.2	Update on Joint FIP/WHO guidelines on good pharmacy practice: standards for quality of pharmacy services	30
9.	Prequalification of priority essential medicines including active pharmaceutical ingredients	30
9.1	Update on the Prequalification of Medicines Programme managed by WHO	30
10.	Prequalification of quality control laboratories	31
10.1	Update on the prequalification of quality control laboratories	31
10.2	Update on the surveys of the quality of medicines	32
11.	Regulatory guidance	32
11.1	Policy on oseltamivir and zanamivir	32
11.2	Assessment criteria for blood regulatory systems	33
11.3	Pharmaceutical development for multisource (generic) pharmaceutical products – points to consider	34
11.4	Guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product: quality part	34
11.5	Development of paediatric medicines: points to consider in pharmaceutical formulation	35
11.6	Provision by health-care professionals of patient-specific preparations for children that are not available as authorized products: points to consider	37
11.7	Quality requirements for artemisinin as a starting material in the production of antimalarial active pharmaceutical ingredients	38
11.8	Update on comparator products	39
12.	Nomenclature, terminology and databases	39
12.1	Quality assurance terminology	39
12.2	International Nonproprietary Names for pharmaceutical substances	40
13.	Miscellaneous	41
13.1	Brochures on the Expert Committee and on quality assurance of pharmaceuticals	41
13.2	Sampling procedures for monitoring of market situations	41
13.3	<i>Index of pharmacopoeias</i>	42
13.4	Collaboration with pharmacopoeias	42
14.	Summary and recommendations	43
	Acknowledgements	51

Annex 1	63
Development of monographs for <i>The International Pharmacopoeia</i>	
Annex 2	67
WHO good manufacturing practices: water for pharmaceutical use	
Annex 3	91
Pharmaceutical development of multisource (generic) pharmaceutical products - point to consider	
Annex 4	121
Guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product for the WHO Prequalification of Medicines Programme: quality part	
Annex 5	197
Development of paediatric medicines: points to consider in formulation	
Annex 6	227
Recommendations for quality requirements for artemisinin as a starting material in the production of antimalarial active pharmaceutical ingredients	